中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 2
Feb.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(2): 246-251

Source and application of seed cells in bioartificial liver support system

DOI: 10.12449/JCH240205
  • 1.

    Shanghai Celliver Biotechnology Co.，Ltd.，Shanghai 201210，China

  • 2.

    Department of Anesthesiology and Critical Care Medicine，Renji Hospital，Shanghai Jiao Tong University School of Medicine，Shanghai 200127，China

Research funding:

National Natural Science Foundation of China (82270635);

Shanghai 2020“Science and Technology Innovation Action Plan” Biomedical Science and Technology Support Project (20S31906600)

More Information
  • Corresponding author: YAN Hexin， hexinyw@163.com （ORCID： 0000-0001-8390-650X）
  • Received Date: 2023-10-25
  • Accepted Date: 2023-11-27
  • Published Date: 2024-02-19
    Abstract
  • So far， there are still no specific treatment methods for severe hepatitis and liver failure， resulting in a mortality rate of over 70%， and they are the difficulties in the treatment of critical illness in China and globally. Liver transplantation is currently the most effective treatment method for end-stage liver disease， but only 1%‍ ‍—‍ ‍2% of patients can receive the opportunity for organ transplantation. The bioartificial liver support system utilizes external mechanical， physical， and biological devices to remove various harmful substances accumulated in the patient’s body， compensate for the metabolic functions of the liver， supplement necessary substances， improve internal environment， promote the recovery of liver function， help patients get through the critical period， and save time for liver transplantation， and therefore， it is considered one of the important methods for the treatment of end-stage liver disease. Since hepatocytes are the core element of bioartificial liver， this article summarizes the sources of liver seed cells， 3D culture methods， and corresponding bioreactor culture systems and hopes to gradually solve the core issue of large-scale in vitro preparation of hepatocytes to obtain hepatocytes with adequate quantity and quality， which urgently needs to be addressed in clinical application.

     

    • FullText(HTML)
  • loading
    • References(53)
  • [1]
    PAN XP, LI LJ. Advances in cell sources of hepatocytes for bioartificial liver[J]. Hepatobiliary Pancreat Dis Int, 2012, 11( 6): 594- 605. DOI: 10.1016/s1499-3872(12)60230-6.
    [2]
    DUAN ZP. Artificial liver technology and its progress[C]∥ Proceedings of the 10th National Military Infectious Disease Academic Symposium. 2007: 82- 84.

    段钟平. 人工肝技术及其进展[C]∥ 全军第十次传染病学学术研讨会论文集. 2007: 82- 84.
    [3]
    GAO YM, SUN LL, HUI LJ. Advances in research of bioartificial liver[J]. Chin Bull Life Sci, 2016, 28( 8): 915- 920. DOI: 10.13376/j.cbls/2016123.

    高义萌, 孙露露, 惠利健. 生物人工肝研究进展[J]. 生命科学, 2016, 28( 8): 915- 920. DOI: 10.13376/j.cbls/2016123.
    [4]
    TUERXUN K, HE JY, IBRAHIM I, et al. Bioartificial livers: A review of their design and manufacture[J]. Biofabrication, 2022, 14( 3): 032003. DOI: 10.1088/1758-5090/ac6e86.
    [5]
    ROZGA J, UMEHARA Y, TROFIMENKO A, et al. A novel plasma filtration therapy for hepatic failure: Preclinical studies[J]. Ther Apher Dial, 2006, 10( 2): 138- 144. DOI: 10.1111/j.1744-9987.2006.00355.x.
    [6]
    DETHLOFF T, TOFTENG F, FREDERIKSEN HJ, et al. Effect of Prometheus liver assist system on systemic hemodynamics in patients with cirrhosis: A randomized controlled study[J]. World J Gastroenterol, 2008, 14( 13): 2065- 2071. DOI: 10.3748/wjg.14.2065.
    [7]
    MATSUMURA KN, GUEVARA GR, HUSTON H, et al. Hybrid bioartificial liver in hepatic failure: Preliminary clinical report[J]. Surgery, 1987, 101( 1): 99- 103.
    [8]
    GARCÍA MARTÍNEZ JJ, BENDJELID K. Artificial liver support systems: What is new over the last decade?[J]. Ann Intensive Care, 2018, 8( 1): 109. DOI: 10.1186/s13613-018-0453-z.
    [9]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
    [10]
    XIANG C, DU Y, MENG G, et al. Long-term functional maintenance of primary human hepatocytes in vitro[J]. Science, 2019, 364( 6438): 399- 402. DOI: 10.1126/science.aau7307.
    [11]
    KATSUDA T, KAWAMATA M, INOUE A, et al. Long-term maintenance of functional primary human hepatocytes using small molecules[J]. FEBS Lett, 2020, 594( 1): 114- 125. DOI: 10.1002/1873-3468.13582.
    [12]
    LIU MY, YANG JC, HU WJ, et al. Superior performance of co-cultured mesenchymal stem cells and hepatocytes in poly(lactic acid-glycolic acid) scaffolds for the treatment of acute liver failure[J]. Biomed Mater, 2016, 11( 1): 015008. DOI: 10.1088/1748-6041/11/1/015008.
    [13]
    HARPER AM, ROSENDALE JD, MCBRIDE MA, et al. The UNOS OPTN waiting list and donor registry[J]. Clin Transpl, 1998: 73- 90.
    [14]
    FACCIOLI LAP, KOCAS-KILICARSLAN ZN, DIAZ-ARAGON R, et al. Human hepatocytes isolated from explanted livers: A powerful tool to understand end-stage liver disease and drug screening[J]. Organogenesis, 2021, 17( 3-4): 117- 125. DOI: 10.1080/15476278.2021.1992216.
    [15]
    MIYAJIMA A, TANAKA M, ITOH T. Stem/progenitor cells in liver development, homeostasis, regeneration, and reprogramming[J]. Cell Stem Cell, 2014, 14( 5): 561- 574. DOI: 10.1016/j.stem.2014.04.010.
    [16]
    TARLOW BD, PELZ C, NAUGLER WE, et al. Bipotential adult liver progenitors are derived from chronically injured mature hepatocytes[J]. Cell Stem Cell, 2014, 15( 5): 605- 618. DOI: 10.1016/j.stem.2014.09.008.
    [17]
    FU GB, HUANG WJ, ZENG M, et al. Expansion and differentiation of human hepatocyte-derived liver progenitor-like cells and their use for the study of hepatotropic pathogens[J]. Cell Res, 2019, 29( 1): 8- 22. DOI: 10.1038/s41422-018-0103-x.
    [18]
    CHEN Y, TANG D, WU HP, et al. Assessment of long-term functional maintenance of primary human hepatocytes to predict drug-induced hepatoxicity in vitro[J]. Arch Toxicol, 2021, 95( 7): 2431- 2442. DOI: 10.1007/s00204-021-03050-y.
    [19]
    ZHANG K, ZHANG LD, LIU WM, et al. In vitro expansion of primary human hepatocytes with efficient liver repopulation capacity[J]. Cell Stem Cell, 2018, 23( 6): 806- 819. DOI: 10.1016/j.stem.2018.10.018.
    [20]
    HU HL, GEHART H, ARTEGIANI B, et al. Long-term expansion of functional mouse and human hepatocytes as 3D organoids[J]. Cell, 2018, 175( 6): 1591- 1606. DOI: 10.1016/j.cell.2018.11.013.
    [21]
    FANG Q, GAO FY, XU M, et al. Treatment of acute liver failure in mice by immortalized human hepatocytes[J]. Chin Med Biotechnol, 2010, 5( 4): 252- 256. DOI: 10.3969/cmba.j.issn.1673-713X.2010.04.003.

    房青, 高福云, 徐梅, 等. 永生化人肝细胞治疗小鼠急性肝衰竭的实验研究[J]. 中国医药生物技术, 2010, 5( 4): 252- 256. DOI: 10.3969/cmba.j.issn.1673-713X.2010.04.003.
    [22]
    ZHANG YF, SHI J, LIU SY. Establishment and characterization of a telomerase-immortalized sheep trophoblast cell line[J]. Biomed Res Int, 2016, 2016: 5808575. DOI: 10.1155/2016/5808575.
    [23]
    LU YZ, LI S, JIANG H, et al. Pre-clinical acute toxicity of an immortalized human hepatocyte cell line HepZJ[J]. Chin J Tissue Engineer Res, 2019, 23( 13): 2067- 2074. DOI: 10.3969/j.issn.2095-4344.1659.

    卢扬洲, 黎少, 姜华, 等. 永生化人肝细胞HepZJ的临床前急性毒性评价[J]. 中国组织工程研究, 2019, 23( 13): 2067- 2074. DOI: 10.3969/j.issn.2095-4344.1659.
    [24]
    LI WJ, ZHU XJ, YUAN TJ, et al. An extracorporeal bioartificial liver embedded with 3D-layered human liver progenitor-like cells relieves acute liver failure in pigs[J]. Sci Transl Med, 2020, 12( 551): eaba5146. DOI: 10.1126/scitranslmed.aba5146.
    [25]
    YANGER K, ZONG YW, MAGGS LR, et al. Robust cellular reprogramming occurs spontaneously during liver regeneration[J]. Genes Dev, 2013, 27( 7): 719- 724. DOI: 10.1101/gad.207803.112.
    [26]
    DUAN YY, CATANA A, MENG Y, et al. Differentiation and enrichment of hepatocyte-like cells from human embryonic stem cells in vitro and in vivo[J]. Stem Cells Dayt Ohio, 2007, 25( 12): 3058- 3068. DOI: 10.1634/stemcells.2007-0291.
    [27]
    WANG YF, ZHENG Q, SUN Z, et al. Reversal of liver failure using a bioartificial liver device implanted with clinical-grade human-induced hepatocytes[J]. Cell Stem Cell, 2023, 30( 5): 617- 631. DOI: 10.1016/j.stem.2023.03.013.
    [28]
    TANG W, GUO R, SHEN SJ, et al. Chemical cocktails enable hepatic reprogramming of human urine-derived cells with a single transcription factor[J]. Acta Pharmacol Sin, 2019, 40( 5): 620- 629. DOI: 10.1038/s41401-018-0170-z.
    [29]
    CHAMULEAU RAFM, DEURHOLT T, HOEKSTRA R. Which are the right cells to be used in a bioartificial liver?[J]. Metab Brain Dis, 2005, 20( 4): 327- 335. DOI: 10.1007/s11011-005-7914-4.
    [30]
    COLTMAN NJ, COKE BA, CHATZI K, et al. Application of HepG2/C3A liver spheroids as a model system for genotoxicity studies[J]. Toxicol Lett, 2021, 345: 34- 45. DOI: 10.1016/j.toxlet.2021.04.004.
    [31]
    ELLIS AJ, HUGHES RD, WENDON JA, et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure[J]. Hepatology, 1996, 24( 6): 1446- 1451. DOI: 10.1002/hep.510240625.
    [32]
    THOMPSON J, JONES N, AL-KHAFAJI A, et al. Extracorporeal cellular therapy(ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial[J]. Liver Transpl, 2018, 24( 3): 380- 393. DOI: 10.1002/lt.24986.
    [33]
    NAGAKI M, NAITO T, OHNISHI H, et al. Effects of plasma from patients with fulminant hepatic failure on function of primary rat hepatocytes in three-dimensional culture[J]. Liver Int, 2005, 25( 5): 1010- 1017. DOI: 10.1111/j.1478-3231.2005.01127.x.
    [34]
    NIBOURG GAA, CHAMULEAU RAFM, VAN DER HOEVEN TV, et al. Liver progenitor cell line HepaRG differentiated in a bioartificial liver effectively supplies liver support to rats with acute liver failure[J]. PLoS One, 2012, 7( 6): e38778. DOI: 10.1371/journal.pone.0038778.
    [35]
    GLORIOSO JM, MAO SA, RODYSILL B, et al. Pivotal preclinical trial of the spheroid reservoir bioartificial liver[J]. J Hepatol, 2015, 63( 2): 388- 398. DOI: 10.1016/j.jhep.2015.03.021.
    [36]
    CHEN HS, JOO DJ, SHAHEEN M, et al. Randomized trial of spheroid reservoir bioartificial liver in porcine model of posthepatectomy liver failure[J]. Hepatology, 2019, 69( 1): 329- 342. DOI: 10.1002/hep.30184.
    [37]
    HE YT, QI YN, ZHANG BQ, et al. Bioartificial liver support systems for acute liver failure: A systematic review and meta-analysis of the clinical and preclinical literature[J]. World J Gastroenterol, 2019, 25( 27): 3634- 3648. DOI: 10.3748/wjg.v25.i27.3634.
    [38]
    LI Y, WU Q, WANG YJ, et al. Novel spheroid reservoir bioartificial liver improves survival of nonhuman primates in a toxin-induced model of acute liver failure[J]. Theranostics, 2018, 8( 20): 5562- 5574. DOI: 10.7150/thno.26540.
    [39]
    MAZARIEGOS GV, KRAMER DJ, LOPEZ RC, et al. Safety observations in phase I clinical evaluation of the excorp medical bioartificial liver support system after the first four patients[J]. ASAIO J, 2001, 47( 5): 471- 475. DOI: 10.1097/00002480-200109000-00015.
    [40]
    MULLON C, PITKIN Z. The HepatAssist bioartificial liver support system: Clinical study and pig hepatocyte process[J]. Expert Opin Investig Drugs, 1999, 8( 3): 229- 235. DOI: 10.1517/13543784.8.3.229.
    [41]
    DEMETRIOU AA, BROWN RS JR, BUSUTTIL RW, et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure[J]. Ann Surg, 2004, 239( 5): 660-667; discussion 667-670. DOI: 10.1097/01.sla.0000124298.74199.e5.
    [42]
    MARTIN U, WINKLER ME, ID M, et al. Productive infection of primary human endothelial cells by pig endogenous retrovirus(PERV)[J]. Xenotransplantation, 2000, 7( 2): 138- 142. DOI: 10.1034/j.1399-3089.2000.00052.x.
    [43]
    FENG L, WANG Y, FU Y, et al. A simple and efficient strategy for cell-based and cell-free-based therapies in acute liver failure: hUCMSCs bioartificial liver[J]. Bioeng Transl Med, 2023, 8( 5): e10552. DOI: 10.1002/btm2.10552.
    [44]
    KNAZEK RA, GULLINO PM, KOHLER PO, et al. Cell culture on artificial capillaries: An approach to tissue growth in vitro[J]. Science, 1972, 178( 4056): 65- 67. DOI: 10.1126/science.178.4056.65.
    [45]
    CASTILLO AB, JACOBS CR. Mesenchymal stem cell mechanobiology[J]. Curr Osteoporos Rep, 2010, 8( 2): 98- 104. DOI: 10.1007/s11914-010-0015-2.
    [46]
    WANG Y, LI H, LI X, et al. Hypoxic preconditioning of human umbilical cord mesenchymal stem cells is an effective strategy for treating acute lung injury[J]. Stem Cells Dev, 2021, 30( 3): 128- 134. DOI: 10.1089/scd.2020.0174.
    [47]
    CHEN ST, WANG JL, REN HZ, et al. Hepatic spheroids derived from human induced pluripotent stem cells in bio-artificial liver rescue porcine acute liver failure[J]. Cell Res, 2020, 30( 1): 95- 97. DOI: 10.1038/s41422-019-0261-5.
    [48]
    LU ZY, PRIYA RAJAN SA, SONG QQ, et al. 3D scaffold-free microlivers with drug metabolic function generated by lineage-reprogrammed hepatocytes from human fibroblasts[J]. Biomaterials, 2021, 269: 120668. DOI: 10.1016/j.biomaterials.2021.120668.
    [49]
    LIU WM, ZHOU X, CHEN CY, et al. Establishment of functional liver spheroids from human hepatocyte-derived liver progenitor-like cells for cell therapy[J]. Front Bioeng Biotechnol, 2021, 9: 738081. DOI: 10.3389/fbioe.2021.738081.
    [50]
    LI K, ZHANG GH, ZHANG C, et al. Assessment of in vitro 3D large-scale hepatocyte proliferation culture system and automated and intelligent bioreactor systems[J]. Chin J Tissue Engineer Res, 2022, 26( 19): 3100- 3107.

    李柯, 张广浩, 张丞, 等. 体外3D规模化扩增肝细胞的培养体系及自动化、智能化生物反应器的评估[J]. 中国组织工程研究, 2022, 26( 19): 3100- 3107.
    [51]
    TEIXEIRA AP, OLIVEIRA R, ALVES PM, et al. Advances in on-line monitoring and control of mammalian cell cultures: Supporting the PAT initiative[J]. Biotechnol Adv, 2009, 27( 6): 726- 732. DOI: 10.1016/j.biotechadv.2009.05.003.
    [52]
    DEMUTH C, VARONIER J, JOSSEN V, et al. Novel probes for pH and dissolved oxygen measurements in cultivations from millilitre to benchtop scale[J]. Appl Microbiol Biotechnol, 2016, 100( 9): 3853- 3863. DOI: 10.1007/s00253-016-7412-0.
    [53]
    RENNEBERG R, TROTT-KRIEGESKORTE G, LIETZ M, et al. Enzyme sensor-FIA-system for on-line monitoring of glucose, lactate and glutamine in animal cell cultures[J]. J Biotechnol, 1991, 21( 1-2): 173- 185. DOI: 10.1016/0168-1656(91)90269-2.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (170) PDF downloads(42) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return